Search and analyze individual stocks with comprehensive metrics
Remus Pharma.
Fundamental Score
Remus Pharma. Share Price & Market Analysis
Profitability Metrics
Return on Equity
Return on Capital Employed
Operating Profit Margin (5Y)
Dividend Yield
Valuation Metrics
Price to Earnings
Market Capitalization
Industry P/E
Growth Metrics
YoY Quarterly Profit Growth
YoY Quarterly Sales Growth
Sales Growth (5Y)
EPS Growth (5Y)
Profit Growth (5Y)
Financial Health
Debt to Equity
Interest Coverage
Free Cash Flow (5Y)
Ownership Structure
Promoter Holding
FII Holding
DII Holding
Pledged Percentage
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Market Data Analysis & Educational Insights
Educational evaluation of REMUS across key market metrics for learning purposes.
Positive Indicators
6 factors identified
Excellent ROCE Performance (19.64%)
Observation: Superior returns on capital employed across business operations.
Analysis: ROCE >15% demonstrates efficient capital deployment and strong operational performance. This indicates quality business fundamentals.
Strong Revenue Growth (88.07%)
Observation: Healthy sales growth indicates market demand and execution capability.
Analysis: Revenue growth >15% suggests strong market position and growth potential. This indicates business expansion success.
Conservative Debt Levels (D/E: 0.09)
Observation: Low leverage provides financial flexibility and reduced risk.
Analysis: Conservative debt structure offers resilience during economic downturns and flexibility for growth investments.
Strong Interest Coverage (33.29x)
Observation: Earnings comfortably cover interest obligations.
Analysis: Interest coverage >5x indicates low financial distress risk and strong debt servicing capability.
Balanced Promoter Holding (70.85%)
Observation: Optimal balance between promoter control and public float.
Analysis: Promoter holding in 50-75% range provides management alignment while ensuring adequate liquidity.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral, reducing forced-selling risk.
Analysis: Absence of share pledging eliminates potential forced-selling pressure during market stress.
Risk Factors
2 factors identified
Limited Institutional Interest (FII+DII: 5.82%)
Observation: Low institutional participation may affect liquidity and visibility.
Analysis: Limited institutional interest may indicate size constraints or visibility issues in the investment community.
High P/E Ratio
Observation: Stock may be overvalued relative to earnings.
Analysis: P/E above 30 requires strong growth execution to justify current valuations.
📊 Educational Market Overview
Disclaimer: The ratings and scores are generated algorithmically from publicly available market data and are provided for educational and informational purposes only. They do not constitute investment advice, recommendation, or solicitation to buy/sell any securities.
Loading Peer Comparison
Finding companies in the Pharmaceuticals sector...
Financial Statements
Comprehensive financial data for Remus Pharma.
About REMUS
Company Details
Market Information
Performance
REMUS Stock Details & Analysis
Key Financial Metrics
Growth & Valuation
Frequently Asked Questions
What is the current price of REMUS?
REMUS is currently trading at ₹789.45 with a gain of 0.00% today. The current market price (CMP) represents the last traded price of REMUS shares on the stock exchange. This price fluctuates throughout trading hours based on supply and demand. You can track real-time price movements, percentage changes, and trading volume in the header section.
What is the P/E ratio of REMUS and what does it mean?
REMUS has a P/E ratio of 32.14x compared to the industry average of 33.97x. The Price-to-Earnings (P/E) ratio is calculated by dividing the current share price by earnings per share (EPS). This means investors are paying ₹32 for every ₹1 of annual earnings. This is lower than the industry average, which might indicate undervaluation or slower growth expectations.
How is REMUS performing according to Bull Run's analysis?
REMUS has a Bull Run fundamental score of 38.2/100, which indicates concerns that require careful analysis. This comprehensive rating is based on 15+ financial parameters including profitability (ROE: 14.00%), growth metrics, valuation ratios, and financial health indicators. The score updates quarterly with new financial data and helps you quickly assess overall investment quality.
What sector and industry does REMUS belong to?
REMUS operates in the Pharmaceuticals & Biotechnology industry. This sector classification helps understand the broader economic trends, regulatory framework, and competitive landscape affecting Remus Pharma.. Companies in this industry typically face similar market dynamics, cyclical patterns, and macroeconomic factors. Understanding the industry context is crucial for peer comparison and assessing how sector-specific trends might impact the stock's performance.
What is Return on Equity (ROE) and why is it important for REMUS?
REMUS has an ROE of 14.00%, which shows decent profitability but room for improvement. Return on Equity measures how efficiently Remus Pharma. generates profits from shareholders' equity. An ROE of 14% means the company generates ₹14 profit for every ₹100 of shareholders' equity. This metric is crucial for assessing management's ability to create value for shareholders.
How is REMUS's debt-to-equity ratio and what does it indicate?
REMUS has a debt-to-equity ratio of 0.09, which indicates conservative financing with low financial risk. This means the company has ₹9 of debt for every ₹100 of equity. This conservative approach provides financial stability but may limit growth potential.
What is REMUS's dividend yield and is it a good dividend stock?
REMUS offers a dividend yield of 0.13%, which means you receive ₹0.13 annual dividend for every ₹100 invested. The focus appears to be more on growth rather than dividend income. Dividend yield is calculated as annual dividend per share ÷ current share price × 100. Evaluate dividend consistency over 5+ years and free cash flow coverage for sustainability.
How has REMUS grown over the past 5 years?
REMUS has achieved 5-year growth rates of: Sales Growth N/A%, Profit Growth N/A%, and EPS Growth N/A%. These growth metrics show the company's ability to expand its business and improve profitability over time. Sales growth indicates market expansion, profit growth shows operational efficiency, and EPS growth directly impacts share price appreciation potential.
What is the promoter holding in REMUS and why does it matter?
Promoters hold 70.85% of REMUS shares, with 0.00% of promoter shares pledged. This high promoter holding indicates strong management confidence and alignment with shareholders. Low pledging indicates financial stability of promoters. Recent change in promoter holding: 0.00%.
How does REMUS compare with its industry peers?
REMUS trades at P/E 32.14x vs industry average 33.97x, with ROE of 14.00% and ROCE of 19.64%. The stock appears undervalued relative to peers based on P/E ratio. Peer comparison helps identify whether REMUS is outperforming its competitive set in profitability, growth, and valuation metrics.
What is REMUS's market capitalization and what category does it fall into?
REMUS has a market capitalization of ₹930 crores, making it a Large-cap stock. Large-cap stocks offer stability and liquidity but typically slower growth. Market cap is calculated as current share price × total outstanding shares, representing the company's total market value.
What are the key financial ratios to consider for REMUS?
Key ratios for REMUS: ROE 14.00% (Good), ROCE 19.64%, P/E 32.14x, Debt-to-Equity 0.09, Interest Coverage 33.29x. These ratios help assess profitability (ROE, ROCE), valuation (P/E), financial health (D/E, Interest Coverage), and overall investment quality. Compare these with industry medians and historical trends for meaningful analysis.
How volatile is REMUS stock and what is its beta?
REMUS has a beta of N/A, which means it is less volatile than the market and offers defensive characteristics. Beta measures price volatility relative to the Nifty 50. Lower beta stocks provide stability during uncertain market conditions. Consider beta alongside your risk tolerance and portfolio diversification strategy.
What is the 52-week high and low for REMUS?
REMUS has a 52-week high of ₹N/A and low of ₹N/A. Currently trading at ₹789.45, the stock is within its annual trading range. Trading near highs indicates strong momentum but limited upside potential.
What are the key risks associated with investing in REMUS?
Key risks for REMUS include: Market volatility (Beta: N/A), financial leverage (Debt-to-Equity: 0.09), and operational challenges. The stock has a Fundamental Score of 38.2/100, indicating higher risk requiring thorough due diligence. Sector-specific risks in Pharmaceuticals & Biotechnology include regulatory changes, economic cycles, and competitive pressures. Consider your risk tolerance, investment horizon, and portfolio diversification before investing. Past performance doesn't guarantee future results.
What is REMUS's operating profit margin and how has it trended?
REMUS has a 5-year average Operating Profit Margin (OPM) of N/A%, which suggests room for improvement in operational efficiency. Operating Profit Margin shows operational efficiency by measuring operating profit as a percentage of revenue. Monitor margin trends to assess management's ability to control costs and improve efficiency. Compare with industry peers to understand relative performance.
How is REMUS's quarterly performance in terms of sales and profit growth?
REMUS's recent quarterly performance shows YoY Sales Growth of 88.07% and YoY Profit Growth of 15.89%. This strong double-digit growth indicates excellent business momentum and management execution. Sales growth shows market demand while profit growth reveals operational efficiency and margin management.
What is the FII and DII holding pattern in REMUS?
REMUS has FII holding of 5.03% and DII holding of 0.79%, totaling 5.82% institutional ownership. This institutional participation level shows the confidence of professional money managers. Monitor quarterly changes in institutional holdings for investment flow trends and sentiment.